European Platform for Regulatory Science Research meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 May 2025, 14:00 (CEST) to 20 May 2025, 16:30 (CEST)

Submission dates

Human medicines European public assessment report (EPAR): Calquence, acalabrutinib, Date of authorisation: 05/11/2020, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Natpar, parathyroid hormone, Date of authorisation: 24/04/2017, Revision: 18, Status: Authorised

Agenda of the COMP meeting 15-17 July 2025

Expected publication dates of PRAC recommendations on safety signals

Agenda of the CVMP meeting 15-17 July 2025

Human medicines European public assessment report (EPAR): Scenesse, afamelanotide, Date of authorisation: 22/12/2014, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Sunlenca, lenacapavir, Date of authorisation: 17/08/2022, Revision: 6, Status: Authorised